- Home
- MYGN vs EQBK Comparison
MYGN vs EQBK Comparison
Compare MYGN & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- EQBK
- Stock Information
- Founded
- MYGN 1991
- EQBK 2002
- Country
- MYGN United States
- EQBK United States
- Employees
- MYGN N/A
- EQBK N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EQBK Major Banks
- Sector
- MYGN Health Care
- EQBK Finance
- Exchange
- MYGN Nasdaq
- EQBK Nasdaq
- Market Cap
- MYGN 744.7M
- EQBK 696.9M
- IPO Year
- MYGN 1995
- EQBK 2015
- Fundamental
- Price
- MYGN $5.34
- EQBK $42.87
- Analyst Decision
- MYGN Hold
- EQBK Buy
- Analyst Count
- MYGN 15
- EQBK 6
- Target Price
- MYGN $15.14
- EQBK $44.40
- AVG Volume (30 Days)
- MYGN 1.3M
- EQBK 83.2K
- Earning Date
- MYGN 08-05-2025
- EQBK 07-14-2025
- Dividend Yield
- MYGN N/A
- EQBK 1.40%
- EPS Growth
- MYGN N/A
- EQBK 543.37
- EPS
- MYGN N/A
- EQBK 3.93
- Revenue
- MYGN $831,300,000.00
- EQBK $224,743,000.00
- Revenue This Year
- MYGN N/A
- EQBK $20.94
- Revenue Next Year
- MYGN $6.68
- EQBK $10.08
- P/E Ratio
- MYGN N/A
- EQBK $10.92
- Revenue Growth
- MYGN 7.38
- EQBK 56.39
- 52 Week Low
- MYGN $3.81
- EQBK $32.95
- 52 Week High
- MYGN $29.30
- EQBK $50.85
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- EQBK 63.84
- Support Level
- MYGN $4.90
- EQBK $43.00
- Resistance Level
- MYGN $5.83
- EQBK $44.32
- Average True Range (ATR)
- MYGN 0.28
- EQBK 1.13
- MACD
- MYGN 0.04
- EQBK 0.24
- Stochastic Oscillator
- MYGN 54.21
- EQBK 73.71
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.